Erratum: Inhibition of OATP1B1 by tyrosine kinase inhibitors: In vitro-in vivo correlations (British Journal of Cancer (2014) 110 (894-898) DOI: 10.1038/bjc.2013.811);Inhibition of OATP1B1 by tyrosine kinase inhibitors: In vitro-in vivo correlations

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 894-898

  Hu, S ^a   Mathijssen, R H J ^b   De Bruijn, P ^b   Baker, S D ^a   Sparreboom, A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SORAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; HEK293 CELLS; HEPATOCYTES; HUMANS; LIVER; MICE; MICE, KNOCKOUT; NIACINAMIDE; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TAXOIDS;

EID: 84894299958     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.217     Document Type: Erratum

References (35)

1. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 118: 63-71.
2. Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, De Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T (2012) Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 48: 465-474.
3. Baker SD, Sparreboom A, Verweij J (2006) Clinical pharmacokinetics of docetaxel: Recent developments. Clin Pharmacokinet 45: 235-252.
4. Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L (2012) Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast 21: 507-513.
5. Chen AA, Thomas DK, Ong LL, Schwartz RE, Golub TR, Bhatia SN (2011) Humanized mice with ectopic artificial liver tissues. Proc Nat Acad Sci USA 108: 11842-11847.
6. Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK (2013) Clinical pharmacology of axitinib. Clin Pharmacokin 52: 713-725.
7. Chiorean EG, Porter JM, Foster AE, Al Omari AS, Yoder CA, Fife KL, Strother RM, Murry DJ, Yu M, Jones DR, Sweeney CJ (2008) A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res 14: 1131-1137.
8. Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC (2011) Docetaxel metabolism is not altered by imatinib: Findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 127: 153-162.
9. De Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, De Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, Van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A (2012) Influence of polymorphic OATP1B-Type carriers on the disposition of docetaxel. Clin Cancer Res 18: 4433-4440.
10. Engel A, Oswald S, Siegmund W, Keiser M (2012) Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm 9: 2577-2581.
11. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, RosenM, O'dwyer PJ (2011) Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: A phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 68: 1111-1118.
12. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ (2008) A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14: 4836-4842.
13. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD (2010) An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88: 652-659.
14. Hamberg P, Mathijssen RHJ, De Bruijn P, Van Der Biessen D, Loos WJ, Sleijfer S, Verweij J, De Jonge MJA (2012) Phase I and pharmacokinetic (PK) study of pazopanib in combination with two schedules of docetaxel (D) in patients (pts) with advanced solid tumors. Eur J Cancer 48(S6): 177 (abstr 579).
15. Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Fan Y, Calabrese C, Rehg JE, Campana D, Rubnitz JE, Baker SD (2011) Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 103: 893-905.
16. Iusuf D, Van De Steeg E, Schinkel AH (2012) Functions of OATP1A and 1B transporters in vivo: Insights from mouse models. Trends Pharmacol Sci 33: 100-108.
17. Konig J, Cui Y, Nies AT, Keppler D (2000) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275: 23161-23168.
18. Konig J, Muller F, Fromm MF (2013) Transporters and drug-drug interactions: Important determinants of drug disposition and effects. Pharmacol Rev 65: 944-966.
19. Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A (2012) OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther 92: 642-650.
20. LoRusso PM, Jones SF, Koch KM, Arya N, Fleming RA, Loftiss J, Pandite L, Gadgeel S, Weber BL, Burris HA III (2008) Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 26: 3051-3056.
21. MalingréMM, Terwogt JM, Beijnen JH, RosingH, Koopman FJ, van TellingenO, Duchin K, Huinink WW, Swart M, Lieverst J, Schellens JH (2000) Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 18: 2468-2475.
22. Manegold C, Gatzemeier U, Buchholz E, Smith RP, Fandi A (2005) A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 6: 343-349.
23. Martin LP, KozloffMF, Herbst RS, Samuel TA, KimS, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB (2012) Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer 107: 1268-1276.
24. Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, Fukino K, Tanigawa T, Nakagawa K (2010) Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 28: 844-853.
25. Reyner EL, Sevidal S, West MA, Clouser-Roche A, Freiwald S, Fenner K, Ullah M, Lee CA, Smith BJ (2013) In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: Implications for disposition and drug interactions. Drug Metab Dispos 41: 1575-1583.
26. Roth M, Obaidat A, Hagenbuch B (2012) OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165: 1260-1287.
27. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I (2010) Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther 332: 181-189.
28. Sugiyama M, Fujita K, Murayama N, Akiyama Y, Yamazaki H, Sasaki Y (2011) Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 10-hydroxylation. Drug Metab Dispos 39: 757-762.
29. Tan AR, Dowlati A, Jones SF, Infante JR, Nishioka J, Fang L, Hodge JP, Gainer SD, Arumugham T, Suttle AB, Dar MM, Lager JJ, Burris III HA (2010) Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 15: 1253-1261.
30. Van De Steeg E, Van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH (2013) Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 19: 821-832.
31. Van Herwaarden AE, Wagenaar E, Van Der Kruijssen CM, VanWaterschoot RA, Smit JW, Song JY, Van Der ValkMA, Van Tellingen O, Van Der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117: 3583-3592.
32. Van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A (1999) Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 5: 2918-2924.
33. Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, Chen EP, Ellens HE, Mooser VE, Cardon LR, Spraggs CF, Pandite L (2010) Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 102: 1371-1377.
34. Ziesenitz VC, Weiss J, Haefeli WE, Mikus G (2013) Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphisms. Clin Pharmacol Ther 93: 388.
35. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, Baker SD (2013) Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19: 1458-1466.